The Incidence and Immunophenotypic and Genetic Features of JL1 Expressing Cells and the Therapeutic Potential of an Anti-JL1 Antibody in De Novo Pediatric Acute Leukemias

Sang Hyuk Park, M.D., Ph.D.1,*, Eunkyoung You, M.D.2,*, Chan-Jeoung Park3, M.D., Ph.D.3, Seongsoo Jang, M.D., Ph.D.3, Young-Uk Cho, M.D., Ph.D.3, Chan Hee Yoon1, Kyung-Nam Koh, M.D., Ph.D.4, Ho-Joon Im, M.D., Ph.D.4, and Jong-Jin Seo, M.D., Ph.D.4

1Department of Laboratory Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea; 2Department of Laboratory Medicine, Inje University College of Medicine, Busan Baik Hospital, Busan, Korea; Departments of 3Laboratory Medicine and 4Pediatrics, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea

Background: JL1 is a newly identified CD43 epitope that specifically recognizes leukemic cells. We analyzed the incidence of JL1 expression and compared the clinical, immunophenotypic, and genetic characteristics of de novo pediatric acute leukemia patients with respect to JL1 expression status to determine the therapeutic potential of an anti-JL1 antibody.

Methods: Seventy-eight patients with pediatric acute leukemia (52 with ALL, 26 with AML) diagnosed between December 2014 and January 2016 were enrolled prospectively. Flow cytometry for JL1 expression was performed at diagnosis. Clinical, immunophenotypic, and genetic characteristics were compared with respect to JL1 expression status by the Student t-test/Mann–Whitney U test and chi-square test/Fisher's exact test.

Results: The incidence of JL1 expression was 76.9% and 84.6% in ALL and AML patients, respectively. ALL patients with JL1 expression showed higher CD10 and cytoplasmic IgM expressions than those without JL1 expression (P=0.022 and 0.003, respectively) and were associated with TCF3-PBX1 and KMT2A-MLLT1 translocations. AML patients with JL1 expression showed higher CD13 and lower CD65 and CD15 expressions than those without JL1 expression (P=0.013, 0.007, and 0.024, respectively) and were associated with RUNX1-RUNX1T1, PML-RARA, and CBFB-MYH11 translocations. The JL1 expression incidence did not differ between ALL and AML, and the JL1 expression status did not affect prognosis.

Conclusions: Our findings support the potential therapeutic role of anti-JL1 monoclonal antibodies; JL1 expression was associated with specific immunophenotypes and genetic abnormalities. Future studies should examine the prognostic impact of JL1 expression in pediatric acute leukemias.

Key Words: Immunophenotypic, Genetic, JL1 expression, Pediatric acute leukemias, Prognosis

INTRODUCTION

Current therapeutic strategies for acute leukemia include induction chemotherapy and additional consolidation or maintenance chemotherapy using cytotoxic agents; however, patients face a high risk of mortality or morbidity during the chemotherapy cy-
Monoclonal antibodies against leukemia-associated antigens induce antibody-dependent cellular cytotoxicity by recruiting tumor cells and exert cytotoxicity via binding to activated immune effector cells. These antibodies could provide an alternative therapeutic strategy to chemotherapy [1-6].

The JL1 antigen is an epitope of CD43, a cell surface glycoprotein of the mucin family. It is also known as a differentiation antigen expressed on double positive (CD4+ CD8+) human cortical thymocytes [6-9]. In normal bone marrow (BM), the JL1 antigen is expressed neither on hematopoietic pluripotent stem cells of myelomonocytic and erythroid lineages nor on mature blood cells (lymphocytes and segmented neutrophils) [7-9]. In contrast, the JL1 antigen is heterogeneously expressed in myelomonocytic lineages (no or weak expression on promyelocytes, myelocytes, and metamyelocytes, but strong expression on band forms); in lymphoid lineages, JL1 antigen is expressed on common lymphoid progenitors and widely distributed during lymphoid maturation but is down-regulated during the final maturation process [7-9]. The JL1 antigen has also been reported to be expressed on leukemic T, B, and myeloid lineage cells in >80% of acute leukemia patients and thus could serve as a potential candidate for immunotherapy [7-9]. The overall incidence of JL1 positivity was reported to be 80.9%, 87.0%, and 90.1% in non-T ALL, T-ALL, and AML, respectively [7]. Preclinical studies have demonstrated the cytotoxic effects of an anti-JL1-based immunotoxin against JL1-positive leukemic cells, which does not affect most normal tissues other than thymocytes and certain mononuclear cells of the BM [10]. A study reported that the JL1 monoclonal antibody recognizes a specific epitope of human CD43 and that saporin conjugated to the JL1 antibody can effectively attack leukemic cells in in vitro cytotoxic assays and result in significantly prolonged survival in a leukemic mouse model [11].

Effective immunotherapy for acute leukemias depends on the exclusive expression of an antigen on leukemic blasts but not on normal hematopoietic cells [12]. Anti-CD20 monoclonal antibody rituximab for B-lineage lymphoma demonstrated the rationale for using immunotherapy in hematologic malignancies [13-16]. Previous studies focused on the treatment of refractory or high-risk acute leukemias. To date, no comprehensive clinical, immunophenotypic, and genetic investigation of JL1-expressing de novo pediatric acute leukemias has been performed. We investigated the incidence of JL1 expression and compared the clinical, immunophenotypic, and genetic characteristics of de novo pediatric acute leukemia patients with respect to JL1 expression status to determine the therapeutic potential of an anti-JL1 monoclonal antibody.

METHODS

Patient cohort and acquisition of clinical and prognostic data
In total, 82 patients with pediatric acute leukemia (52 ALL [48 B-ALL and four T-ALL] and 30 AML) diagnosed between December 2014 and January 2016 at Asan Medical Center, Seoul, Korea, were initially enrolled. Four AML patients who were identified as having secondary AML, such as therapy-related AML or AML with myelodysplasia-related changes, were subsequently excluded. We finally included 78 patients diagnosed as having de novo pediatric acute leukemia (52 ALL and 26 AML) with a median age of 96 months (range: 2–216 months) and a median follow-up period of 424 days (range: 79–753 days). This prospective study was conducted in accordance with the Declaration of Helsinki (2013 revision), and written informed consent was obtained from all patients. It was approved by the Institutional Review Board (IRB) of Asan Medical Center, Seoul, Korea (approval number: AMC IRB 2014-0066).

Clinical characteristics, including sex, age, hemogram results, and blast proportions in peripheral blood (PB) and BM at diagnosis, were collected. The prognostic indicator period from diagnosis to first hematologic complete remission (CR), rate of hematologic CR achievement, and relapse rate in patients with first hematologic CR were analyzed. Hematologic CR was defined as meeting all of the following response criteria during evaluation at least four weeks post diagnosis: <5% blasts in the BM and no blasts in the PB, normal maturation of all cellular components in the BM, no evidence of extramedullary diseases (such as involvement of the central nervous system or soft tissue), absolute neutrophil count ≥1×10^9/L, platelet count ≥100×10^9/L, and a clinically proven transfusion independent state. Relapse was defined as the presence of ≥5% leukemic blasts in the BM aspirates in patients with a previously hematologic CR state.

Treatment strategies
Patients diagnosed as having ALL received induction chemotherapy comprising vincristine, corticosteroids, and L-asparaginase with added anthracycline. In addition, intrathecal chemotherapy was administered with methotrexate for standard-risk patients and with corticosteroid and cytarabine for high-risk patients, such as those with T-ALL or a complex karyotype. Following induction chemotherapy and achievement of hematologic CR, consolidation chemotherapy typically lasting one to two months.
was conducted with methotrexate and 6-mercaptopurine or 6-thioguanine for standard-risk patients; L-asparaginase, doxorubicin, etoposide, cyclophosphamide, and cytarabine for high-risk patients; and a tyrosine kinase inhibitor for patients with t(9;22)(q34;q11.2). Following consolidation chemotherapy, maintenance chemotherapy typically lasting 16 weeks was performed; the most commonly applied treatment regimen was administration of 6-mercaptopurine daily and methotrexate weekly, administered as pills, often together with vincristine (administered intravenously) and a corticosteroid (administered orally). The latter two drugs were administered once after every four to eight weeks.

Patients diagnosed as having AML received induction chemotherapy (7+3 regimen) with a continuous infusion of cytarabine at a dosage of 100–200 mg/m² per day on days 1 to 7 and daunorubicin at 60 mg/m² per day on days 1 to 3. Following hematologic CR, patients received high-dose cytarabine-based consolidation chemotherapy using cytarabine twice daily at a 3 g/m² dose on days 1, 3, and 5, or received hematopoietic stem cell transplantation according to the eligibility of hematopoietic stem cell donors. In cases of acute promyelocytic leukemia, patients received induction chemotherapy consisting of all-trans retinoic acid (ATRA) plus daunorubicin and/or cytarabine, as well as consolidation chemotherapy with similar regimens.

**Immunophenotyping**

Flow cytometry for immunophenotyping leukemic blasts was performed with a FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA). For ALL, CD45, CD34, terminal deoxynucleotidyl transferase (TdT), CD13, CD33, CD10, CD19, CD20, cytoplasmic CD22 (cCD22), CD2, CD3, cytoplasmic CD3 (cCD3), CD5, CD7, CD56, cytoplasmic IgM (cIgM), surface IgM (sIgM), and myeloperoxidase (MPO) were included in the analysis. For AML, CD45, CD34, TdT, CD13, CD33, CD10, CD19, cCD22, CD2, CD3, cCD3, CD7, CD56, MPO, HLA-D related (HLA-DR), CD117, CD65, CD15, CD14, and CD41 were included in the analysis.

Expression of JL1 on the leukemic blasts was also examined using FACSCanto II. At least 20,000 nucleated cells were acquired per tube, and leukemic blasts were isolated based on weak to intermediate expression of CD45-allophycocyanin (APC)/low side scattering (SSC) gating. The proportion of JL1 expressing

---

**Fig. 1.** Schematic illustration of JL1 expression analysis by flow cytometry. The initial cutoff threshold of fluorescence intensity for positive expression of JL1 determined using isotypic controls was validated with an internal control (lymphocytes) (A). JL1 expression in myeloid immature cells, and B-ALL examples of JL1 expression and without JL1 expression in leukemic blasts are given in (B-D), respectively (5.8%, 90.8%, and 3.9%, respectively).

Abbreviations: CD, cluster of differentiations; SSC, side scattering; FSC, forward scattering; PE, phycoerythrin; APC, allophycocyanin.
leukemic blasts among the gated leukemic blasts was calculated based on the forward scattering (FSC) vs JL1-phycocerythrin (PE) dot plot. The results of the JL1 expression analysis are presented as the proportion of JL1-positive cells among the gated leukemic blasts (Fig. 1). The cutoff threshold of the fluorescence intensity for positive JL1 expression was initially determined using isotypic controls, and its validity was finally confirmed using an internal control (lymphocytes without JL1 expression) for each analysis. Positive JL1 expression was defined as ≥20% expression among the gated leukemic blasts. All antibodies except the ones for CD45 (BD Biosciences) and JL1 (Dinona Inc., Seoul, Korea) were provided by Beckman-Coulter (Miami, FL, USA).

Genetic analysis
Conventional karyotype analysis was performed for all patients at diagnosis. HemaVision (DNA Diagnostic, Risskov, Denmark) PCR and direct sequencing for the detection of fms-related tyrosine kinase 3 gene internal tandem duplications (FLT3-ITD), FLT3-tyrosine kinase domain (TKD), nucleophosmin (NPM1), c-KIT, and CCAAT/enhancer-binding protein-α (CEBPA) mutations were also performed at diagnosis. In addition, the proportion of recurrent genetic abnormalities (RGA), defined in the 2016 WHO classification, were calculated [17].

Statistical analysis
The Kolmogorov–Smirnov test was performed to assess the normality of the distribution of continuous variables. Normally distributed continuous variables were summarized as mean and SD and compared using the Student t-test. Non-normally distributed continuous variables were summarized as median and range and compared using the Mann–Whitney U test. Dichotomous variables were summarized as number and percentage and compared using Pearson’s chi-square test and Fisher’s exact test (for N<5). All tests were two-tailed. P≤0.05 was considered statistically significant. All tests were performed using SPSS for Windows, version 21.0 (IBM Corp., Armonk, NY, USA).

RESULTS

Comparison by disease subgroups
ALL patients were younger than AML patients at diagnosis (median 67 vs 156 months, P<0.001), and their periods from diagnosis to achievement of first hematologic CR were shorter (median 33 vs 50 days, P=0.001). However, no other clinical variables differed significantly between ALL and AML patients, nor did JL1 expression in leukemic blasts and JL1 incidence (mean 50.69% vs 54.41%, P=0.642 and 76.9% vs 84.6%, P=0.557, respectively; Table 1).

ALL patients
The clinical characteristics, including prognosis, of the 48 B-ALL patients did not significantly differ with respect to the JL1 expression status. The patients with positive JL1 expression showed higher JL1 expression in leukemic blasts than those without JL1 expression (P<0.001). Notably, the patients with positive JL1 expression showed higher CD10 and clgM expressions in leukemic blasts than those without JL1 expression (P=0.022 and 0.003, respectively).

The patients with positive JL1 expression also showed a high incidence of TCF3-PBX1 (N=6) and KMT2A-MLLT1 (N=2) rearrangement (detected by PCR), indicating the presence of t(1;19)(q23;p13.3) and t(11;19)(q23;p13.3) chromosomal aberrations, respectively. The presence of these two chromosomal aberrations in eight patients was further confirmed by karyotype analysis. These two genetic abnormalities were not observed in patients without JL1 expression (Table 2).

Four T-ALL patients exhibited JL1 expression (median, 45.0%; range, 31.6–88.2%), and their karyotype was normal, complex, hyperdiploidy, and add(7)(q22), respectively (data not shown).

AML patients
The clinical characteristics, including prognosis, of the 26 AML patients did not significantly differ with respect to the JL1 expression status. Patients with positive JL1 expression showed higher JL1 expression in leukemic blasts than those without JL1 expression (P=0.002). Notably, the patients with positive JL1 expression showed higher CD13 expression (P=0.013) and lower CD65 and CD15 expressions (P=0.007 and 0.024, respectively) in leukemic blasts than those without JL1 expression.

The patients with positive JL1 expression also showed a high incidence of RUNX1-RUNXI1 (N=6), CBFB-MYH11 (N=3), and PML-RARA (N=2) rearrangements (detected by PCR), indicating the presence of t(8;21)(q22;q22), inv(16)(p13.1q22), and t(15;17)(q24;q21) chromosomal aberrations, respectively. The presence of these three chromosomal aberrations in 11 patients was further confirmed by karyotype analysis. These three genetic abnormalities were not observed in patients without JL1 expression.

Patients with positive JL1 expression showed an incidence of 27.3%, 18.2%, and 4.5% for the FLT3-ITD, c-KIT, and NPM1 mutations, respectively; patients without JL1 expression showed an NPM1 mutation incidence of 25.0%. However, the incidences
### Table 1. Comparison of clinical characteristics and JL1 expression status in 78 de novo pediatric acute leukemia patients at diagnosis with respect to disease subgroups

| Variables                             | ALL (N = 52) | AML (N = 26) | P       |
|---------------------------------------|--------------|--------------|---------|
| Sex (M : F)                           | 27 : 25      | 15 : 11      | 0.630†  |
| Age (month)*                          | 67.0 (2.0–216.0) | 156.0 (18.0–216.0) | <0.001‡ |
| WBC (×10⁹/L)                          | 51.86 ± 113.09 | 94.20 ± 149.10 | 0.166†  |
| Hb (×10 g/L)                          | 8.14 ± 2.46  | 7.17 ± 1.60  | 0.072†  |
| PLT (×10⁹/L)                          | 69,650 ± 57,410 | 93,810 ± 104,310 | 0.190†  |
| Blast in PB (%)                       | 54.27 ± 33.02 | 50.77 ± 35.10 | 0.667‡  |
| Blast in BM (%)                       | 83.15 ± 17.15 | 73.68 ± 23.46 | 0.046‡  |
| Days from Dx to 1st CR*               | 33.0 (13.0–182.0) | 50.0 (27.0–285.0) | 0.001‡  |
| Hematologic CR achievement            | 51/52 (98.1%) | 23/26 (88.5%) | 0.070§  |
| Relapse after 1st CR                  | 5/51 (9.80%) | 4/23 (17.4%) | 0.446§  |
| JL1 expression (%)                    | 50.69 ± 32.23 | 54.41 ± 34.95 | 0.642§  |
| JL1 incidence                         | 40/52 (76.9%) | 22/26 (84.6%) | 0.553§  |
| RGA from PCR                          | 19/52 (36.5%) | 14/26 (53.8%) | 0.145§  |

**PCR results (N of patients)**

- **FUS-ERG** (2)
- **KMT2A-AFF1** (2)
- **ETV6-RUNX1** (6)
- **BCR-ABL1** (3)
- **TCF3-PBX1** (6)
- **KMT2A-MLLT1** (2)
- **KMT2A-MLLT3** (3)
- **RUNX1-RUNX1T1** (6)
- **PML-RARA** (2)
- **CBFB-MYH11** (3)
- **SET-NUP214** (1)
- **Normal** (11)
- **NA**

**Karyotype results (N of patients)**

- **add(7)(q22) (1)**
- **add(9)(p21) (1)**
- **t(9;22)(q34;q11.2) (3)**
- **complex (7)**
- **del(9q) (2)**
- **+10 (1)**
- **t(16;21)(p11.2;q22) (2)**
- **hyperdiploidy (10)**
- **t(4;11)(q21;q23) (2)**
- **t(11;19)(q23;p13.3) (2)**
- **t(8;9)(q24.3;p13) (1)**
- **t(2;16)(p11.2;p11.2) (1)**
- **t(1;19)(q23;13.3) (6)**
- **Normal** (13)
- **add(15)(p13.1q22) (3)**
- **complex (3)**
- **del(13q) (1)**
- **del(9q) (1)**
- **t(9;11)(q22;q23) (3)**
- **t(15;17)(q24;q21) (2)**
- **t(8;21)(q22;q22) (6)**
- **+8 (2)**
- **Normal** (5)

*These variables did not show normal distribution in the Kolmogorov–Smirnov test; thus, the median values and ranges are presented. All other continuous variables are presented as mean±SD.

P values were obtained from the Student t-test*, Mann–Whitney U test† and chi-square/Fisher’s exact test‡; *The 52 patients with ALL included 48 patients with B-ALL and 4 patients with T-ALL.

Abbreviations: M, male; F, female; WBC, white blood cells; PLT, platelets; PB, peripheral blood; BM, bone marrow; Dx, diagnosis; CR, complete remission; RGA, recurrent genetic abnormalities included in the 2016 WHO classification; NA, not applicable; add, addition; t, translocation; inv, inversion; del, deletion.
Table 2. Comparison of the clinical, immunophenotypic, and genetic characteristics of 48 de novo pediatric B-ALL patients at diagnosis with respect to JL1 expression status

| Variables                                      | JL1 negative (N = 12) | JL1 positive (N = 36) | P    |
|-----------------------------------------------|-----------------------|-----------------------|------|
| Sex (M : F)                                   | 6 : 6                 | 18 : 18               | 0.999 |
| Age (month)                                   | 84.8 ± 64.7           | 72.3 ± 52.6           | 0.506 |
| WBC (× 10^9 /L)                                | 77.15 ± 169.10        | 47.99 ± 95.99         | 0.461 |
| Hb (× 10^12 /L)                                | 9.03 ± 3.01           | 9.38 ± 10.49          | 0.910 |
| PLT (× 10^9 /L)                                | 56.000 ± 48.090       | 70.670 ± 60.310       | 0.449 |
| Blast in PB (%)                               | 65.00 ± 30.93         | 54.36 ± 32.72         | 0.328 |
| Blast in BM (%)                               | 83.85 ± 17.00         | 84.02 ± 15.11         | 0.975 |
| Days from Dx to 1st CR                        | 60.5 ± 47.3           | 45.8 ± 36.3           | 0.268 |
| Hematologic CR achievement (%)                | 12/12 (100.0%)        | 35/36 (97.2%)         | 0.560 |
| Relapse after 1st CR (%)                      | 3/12 (25.0%)          | 2/35 (5.7%)           | 0.097 |
| JL1 expression* (%)                           | 5.60 (1.00–19.00)     | 65.23 (20.00–99.00)   | < 0.001 |
| CD45 expression (%)                           | 76.09 ± 29.20         | 82.97 ± 16.63         | 0.316 |
| CD34 expression (%)                           | 38.34 ± 42.69         | 51.17 ± 40.34         | 0.352 |
| TdT expression (%)                            | 53.51 ± 28.69         | 59.09 ± 29.06         | 0.566 |
| CD13 expression (%)                           | 13.04 ± 17.62         | 9.13 ± 15.73          | 0.474 |
| CD33 expression (%)                           | 8.98 ± 16.68          | 10.55 ± 22.27         | 0.825 |
| CD10 expression* (%)                          | 67.40 (0.00–94.00)    | 93.70 (0.00–99.00)    | 0.022 |
| CD19 expression (%)                           | 75.83 ± 24.79         | 82.75 ± 17.31         | 0.289 |
| CD20 expression (%)                           | 11.55 ± 23.49         | 10.12 ± 16.15         | 0.815 |
| cCD22 expression (%)                          | 31.72 ± 28.52         | 35.75 ± 29.16         | 0.679 |
| cIgM expression* (%)                          | 2.35 (0.00–7.00)      | 7.00 (0.00–85.00)     | 0.003 |
| sIgM expression (%)                           | 3.08 ± 4.15           | 4.94 ± 5.47           | 0.285 |
| RGA from PCR (%)                              | 4/12 (33.3%)          | 15/36 (41.7%)         | 0.739 |
| PCR results (N of patients)                   |                       |                       |      |
| ETV6-RUNX1 (2)                                |                       |                       |      |
| BCR-ABL1 (1)                                  |                       |                       |      |
| FUS-ERG (1)                                   |                       |                       |      |
| KMT2A-AFF1 (1)                                |                       |                       |      |
| Normal (7)                                    |                       |                       |      |
| PCR results (N of patients)                   |                       |                       |      |
| ETV6-RUNX1 (4)                                |                       |                       |      |
| BCR-ABL1 (2)                                  |                       |                       |      |
| FUS-ERG (1)                                   |                       |                       |      |
| KMT2A-AFF1 (1)                                |                       |                       |      |
| TCFL-PAK1 (6)                                 |                       |                       |      |
| KMT2A-MLLT1 (2)                               |                       |                       |      |
| Normal (20)                                   |                       |                       |      |
| Karyotype results (N of patients)             |                       |                       |      |
| Hyperdiploidy (3)                             |                       |                       |      |
| t(8;9)(q24.3;p13) (1)                         |                       |                       |      |
| t(16;21)(p11.2;q22) (1)                       |                       |                       |      |
| t(9;22)(q34;q11.2) (1)                        |                       |                       |      |
| t(4;11)(q21;q23) (1)                          |                       |                       |      |
| Normal (4)                                    |                       |                       |      |
| Karyotype results (N of patients)             |                       |                       |      |
| Hyperdiploidy (6)                             |                       |                       |      |
| t(9;22)(q34;q11.2) (2) (complex 5)            |                       |                       |      |
| del(9p) (2)                                   |                       |                       |      |
| +10 (1)                                       |                       |                       |      |
| t(16;21)(p11.2;q22) (1)                       |                       |                       |      |
| t(4;11)(q21;q23) (1)                          |                       |                       |      |
| Normal (8)                                    |                       |                       |      |

* These variables did not show normal distribution in the Kolmogorov–Smirnov test; thus, the median values and ranges are presented. All other continuous variables are presented as mean±SD.

P values were obtained from the Student t-test*, Mann–Whitney U test† and chi-square/Fisher's exact test‡.

Abbreviations: M, male; F, female; WBC, white blood cells; PLT, platelets; PB, peripheral blood; BM, bone marrow; Dx, diagnosis; CR, complete remission; RGA, recurrent genetic abnormalities included in the 2016 WHO classification; NA, not applicable; CD, cluster of differentiations; TdT, terminal deoxynucleotidyld transferase; c, cytoplasmic; s, surface; t, translocation; add, addition; del, deletion.
Table 3. Comparison of the clinical, immunophenotypic, and genetic characteristics of 26 de novo pediatric AML patients at diagnosis with respect to JL1 expression status

| Variables                        | JL1 negative (N = 4) | JL1 positive (N = 22) | P     |
|----------------------------------|----------------------|-----------------------|-------|
| Sex (M : F)                      | 3 : 1                | 12 : 10               | 0.614 |
| Age (month)                      | 100.5 ± 83.62        | 142.9 ± 57.34         | 0.214 |
| WBC (× 10^9/L)                   | 31.77 ± 59.81        | 105.55 ± 158.35       | 0.373 |
| Hb (× 10 g/L)                    | 8.33 ± 1.56          | 6.96 ± 1.55           | 0.119 |
| PLT (× 10^9/L)                   | 86,750 ± 42,360      | 95,090 ± 112,630      | 0.887 |
| Blast in PB (%)                  | 19.25 ± 33.89        | 56.50 ± 32.85         | 0.049 |
| Blast in BM (%)                  | 64.00 ± 38.82        | 75.45 ± 20.47         | 0.380 |
| Days from Dx to 1st CR           | 95.0 ± 62.7          | 83.9 ± 74.7           | 0.786 |
| Hematologic CR achievement (%)   | 4/4 (100.0)          | 19/22 (86.4)          | 0.432 |
| Relapse after 1st CR (%)         | 2/4 (50.0)           | 2/19 (10.5)           | 0.125 |
| JL1 expression* (%)              | 4.30 (1.00–8.00)     | 59.45 (21.00–100.00)  | 0.002 |
| CD45 expression (%)              | 61.95 ± 26.96        | 72.30 ± 19.30         | 0.361 |
| CD34 expression (%)              | 13.23 ± 25.25        | 42.80 ± 34.64         | 0.119 |
| TdT expression (%)               | 0.60 ± 0.52          | 4.24 ± 34.64          | 0.213 |
| CD13 expression (%)              | 42.95 ± 34.37        | 78.29 ± 22.29         | 0.013 |
| CD33 expression (%)              | 90.20 ± 14.71        | 74.87 ± 25.95         | 0.267 |
| CD10 expression (%)              | 0.55 ± 0.47          | 3.04 ± 8.70           | 0.579 |
| CD19 expression (%)              | 5.55 ± 7.88          | 9.78 ± 19.57          | 0.678 |
| cCD22 expression (%)             | 0.78 ± 0.35          | 1.31 ± 2.22           | 0.639 |
| CD2 expression (%)               | 1.58 ± 1.45          | 7.82 ± 12.77          | 0.346 |
| CD7 expression (%)               | 1.63 ± 2.07          | 14.58 ± 24.18         | 0.303 |
| CD56 expression (%)              | 31.15 ± 41.83        | 21.80 ± 32.87         | 0.695 |
| MPO expression (%)               | 13.15 ± 20.92        | 28.73 ± 28.71         | 0.314 |
| HLA-DR expression (%)            | 92.20 ± 9.68         | 64.64 ± 37.31         | 0.161 |
| CD117 expression (%)             | 43.10 ± 25.91        | 55.77 ± 32.67         | 0.472 |
| CD65 expression (%)              | 72.28 ± 29.71        | 31.50 ± 24.82         | 0.007 |
| CD15 expression (%)              | 69.55 ± 35.64        | 35.27 ± 24.43         | 0.024 |
| CD14 expression (%)              | 1.48 ± 0.92          | 9.90 ± 17.30          | 0.348 |
| CD41 expression (%)              | 2.40 ± 1.77          | 3.10 ± 3.62           | 0.714 |
| FLT3-ITD mutation (%)            | 0/4 (0.0%)           | 0/22 (0.0%)           | NA   |
| FLT3-ITD mutation (%)            | 0/4 (0.0%)           | 6/22 (27.3%)          | 0.542 |
| c-KIT mutation (%)               | 0/4 (0.0%)           | 4/22 (18.2%)          | 0.354 |
| NPM1 mutations (%)               | 1/4 (25.0%)          | 1/22 (4.5%)           | 0.289 |
| CEBPA mutations (%)              | 0/4 (0.0%)           | 0/22 (0.0%)           | NA   |
| RGA from PCR (%)                 | 2/4 (50.0%)          | 12/22 (54.5%)         | 0.867 |
| PCR results (N of patients)       |                        |                       |       |
| Normal (2)                       |                       |                       |       |
| KMT2A-MLLT3 (1)                  |                       |                       |       |
| RUNX1-RUNX1T1 (6)                |                       |                       |       |
| PML-RARA (2)                     |                       |                       |       |
| CBFB-MYH11 (3)                   |                       |                       |       |
| SET-NUP214 (1)                   |                       |                       |       |
| Normal (9)                       |                       |                       |       |

(Continued to the next page)
of these three genetic mutations (FLT3-ITD, c-KIT, and NPM1) did not differ significantly with respect to the JL1 expression status (Table 3).

**DISCUSSION**

We found that the incidence of positive JL1 expression was 76.9% and 84.6% in de novo pediatric ALL and AML patients, respectively. Although these results are slightly lower than those reported previously (80.9–87.0% for ALL and 90.1% for AML) [7], we demonstrated that approximately 80% of de novo pediatric acute leukemia patients significantly express JL1 antigens in leukemic blasts. This finding may provide an adequate rationale for using the JL1 antigen as a candidate target for immunotherapy.

In addition, we found that all patients with positive JL1 expression have higher CD10 and cIgM expressions than those without JL1 expression. As the absolute value of cIgM expression was low, we hypothesize that the clinical significance of differences in cIgM expression is limited. However, the absolute value of CD10 expression in leukemic blasts of patients with positive JL1 expression was high, suggesting that pediatric patients with CD10-expressed common cell ALL are more likely to benefit from anti-JL1 immunotherapy than other patients. The heterogeneous expression of the JL1 antigen on CD34+ and CD10+ lymphoid precursors was also reported in a previous study [11], which supports our results. In addition, we demonstrated that only de novo pediatric ALL patients with positive JL1 expression have TCF3-PBX1 and KMT2A-MLLT1 rearrangements, indicating the presence of t(1;19)(q23;p13.3) and t(11;19)(q23;p13.3) chromosomal abnormalities, respectively. Our results also suggest that anti-JL1 immunotherapy could be an additional therapeutic option for pediatric ALL patients who harbor TCF3-PBX1 and KMT2A-MLLT1 rearrangements, which result in a poor prognosis in infantile leukemia.

Interestingly, our results showed that all four T-ALL patients exhibited JL1 expression, which may indicate that the incidence of JL1 expression in pediatric T-ALL might be higher than in pediatric B-ALL. However, as the number of pediatric T-ALL patients included in our study was very limited, this result should be interpreted with much caution and should be further addressed in future studies.

Compared with ALL, the number of pediatric AML patients without JL1 expression was low, and the statistical power was limited. However, we demonstrated that de novo pediatric AML patients with positive JL1 expression have higher CD13 and lower CD65 and CD15 expressions than those without JL1 expression. These results suggest that pediatric AML patients with positive JL1 expression tend to present a more immature leukemic blast immunophenotype (lower expression of the granulocytic maturation markers CD65 and CD15) than those without JL1 expression.

We also showed that de novo pediatric AML patients with positive JL1 expression, but not those without JL1 expression, exclusively present with RUNX1-RUNX1T1, CBFB-MYH11, and PML-RARA rearrangements, which indicate the presence of t(8;21)(q22;q22), inv(16)(p13.1q22), and t(15;17)(q24;q21) chromosomal abnormalities. These results suggest that the application

| Variables                      | JL1 negative (N = 4) | JL1 positive (N = 22) | P  |
|-------------------------------|----------------------|-----------------------|----|
| Karyotype results (N of patients) |                       |                       |    |
| +8 (1)                        | inv(16)(p13.1q22) (3) complex (2) |                       |    |
| t(9;11)(p22;q23) (1) complex (1) |                       |                       |    |
| Normal (1)                    |                       |                       |    |
| del(9q) (1)                   | t(9;11)(p22;q23) (2)  |                       |    |
| t(15;17)(q24;q21) (2)         |                       |                       |    |
| t(8;21)(q22;q22) (6)          | +8 (1)                |                       |    |
| Normal (4)                    |                       |                       |    |

* This variable did not show normal distribution in the Kolmogorov–Smirnov test; thus, the median values and ranges are presented. All other continuous variables are presented as mean±SD.

P values were obtained from the Student t-test, Mann–Whitney U test and chi-square/Fisher’s exact test.

Abbreviations: M, male; F, female; WBC, white blood cells; PLT, platelets; PB, peripheral blood; BM, bone marrow; Dx, diagnosis; CR, complete remission; RGA, recurrent genetic abnormalities included in the 2016 WHO classification; MPO, myeloperoxidase; NA, not applicable; CD, cluster of differentiations; TdT, terminal deoxynucleotidyl transferase; c, cytoplasmic; MPO, myeloperoxidase; FLT3-ITD, fms-related tyrosine kinase 3 gene internal tandem duplications; TKD, tyrosine kinase domain; NPM1, nucleophosmin; CEBPA, CCAAT/enhancer binding protein-α; t, translocation; inv, inversion; del, deletion.
of anti-JL1 immunotherapy could be an additional therapeutic option for pediatric patients with core binding factor (CBF) AML and acute promyelocytic leukemia.

Moreover, although the differences were not statistically significant, we found that the incidence of the poor prognostic marker, FLT3-ITD and c-KIT mutations, is higher, and that of favorable prognostic markers, such as NPM1 mutations, is lower in de novo pediatric AML patients with positive JL1 expression than in those without JL1 expression. These results suggest that anti-JL1 immunotherapy could be an additional therapeutic option for pediatric AML patients who harbor poor molecular prognostic markers. Although a previous study suggested that a gelonin-conjugated anti-JL1 monoclonal antibody immunotoxin could be developed as a potential immunotherapeutic agent for treating various types of JL1-positive acute leukemias [10], the therapeutic effect of the JL1 monoclonal antibody has not been validated by well-designed clinical trials. Our study supports the application potential of the anti-JL1 monoclonal antibody, especially when conjugated with toxic substances, for the treatment of JL1-expressing pediatric acute leukemias. Well-designed clinical trials focused on this issue are required to further validate this proposed therapy option.

Our study has major limitations in terms of statistical power due to the small number of patients in each subgroup, and insufficient analysis of prognosis, including overall and event free survival, due to high hematologic CR rates and low relapse rates. All our suggestions should be confirmed with large-scale comprehensive studies, and the prognostic value of JL1 antigen expression needs to be investigated using well-controlled prospective studies.

In conclusion, we showed that 76.9% and 84.6% of de novo pediatric ALL and AML patients demonstrated positive JL1 expression, which supports the potential therapeutic role of anti-JL1 monoclonal antibodies. Positive JL1 expression cases were associated with specific immunophenotypic features and genetic abnormalities; however, the JL1 expression status did not significantly affect prognosis. This should be further examined in more comprehensive studies.

**Authors’ Disclosures of Potential Conflicts of Interest**

No potential conflicts of interest relevant to this article were reported.

**REFERENCES**

1. Adams GP and Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
2. Gasparini G, Longo R, Torino F,Gattuso D, Morabito A, Toffoli G. Is tailored therapy feasible in oncology? Crit Rev Oncol Hematol 2006;57:79-101.
3. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005;23:1073-8.
4. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG1 Fc receptor FcgammaRIIa gene. Blood 2002;99:754-8.
5. Weng WK and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
6. Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FcGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-9.
7. Shin YK, Choi EY, Kim SH, Chung J, Chung DH, Park WS, et al. Expression of leukemia-associated antigen, JL1, in bone marrow and thymus. Am J Pathol 2001;158:1473-80.
8. Chung JK, So Y, Hong MK, Choi SR, Jeong JM, Lee DS, et al. In vitro and in vivo properties of murine monoclonal antibody for a novel immature thymocyte-differentiated antigen, JL1. Nucl Med Biol 1997;24:433-7.
9. Park WS, Bae YM, Chung DH, Kim TJ, Choi EY, Chung JK, et al. A cell surface molecule, JL1: a specific target for diagnosis and treatment of leukemia. Leukemia 1998;12:1583-90.
10. Shin YK, Choi YL, Choi EY, Kim MK, Kook MC, Chung J, et al. Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications. Cancer Immunol Immunother 2003;52:506-12.
11. Jeon YK, Min HS, Lee YJ, Kang BH, Kim EJ, Park HJ, et al. Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia. Cancer Immunol Immunother 2011;60:1697-706.
12. Scott AM, Walcheck JD,Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278-87.
13. Tíbes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, et al. Activity of alemtuzumab in patients with CD52-negative acute leukemia. Cancer 2006;106:2645-51.
14. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol 2008;26:3756-62.
15. Kantarjian HM, DeAngelo DJ, Steljes M, Martirelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016;375:740-53.
16. Kantarjian H, Stein A, Gökbüget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017;376:836-47.
17. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of hematopoietic and lymphoid tissues. Revised 4th ed. Lyon: IARC Press, 2016.